Integrin Activation

As a novel therapeutic modality


Our Clinical Lead


Ontegimod is an oral, small molecule, selective agonist of integrin CD11b. It is being developed for the treatment of nephritis (kidney disease) associated with systemic lupus erythematosus.


Lupus Nephritis (LN) is a chronic kidney disease that occurs in up to half of patients with Systemic Lupus Erythematosus (SLE, lupus).

Currently, there is no consistent treatment for LN, and patients often rely on broad immunosuppressive courses. In refractory cases, dialysis and/or transplantation become necessary.

Ontegimod is expected to effectively prevent inflammatory kidney damage without the toxicity and side effects associated with strong immunosuppressants, owing to the autoimmune nature of the disease.


Mechanism of Action

Ontegimod binds and activates CD11b on macrophages (the body’s immune cells), suppressing TLR-driven inflammation.

This leads to less inflammation in the glomeruli of the kidney, without suppressing adaptive immune system pathways.


Targeted immunosuppressant


Efficacy with less side effects

Other Therapeutics

Details coming soon...

© 2023 AlloSite Therapeutics.       All rights reserved.